Wells Fargo lowered the price target for the MEI Pharma Inc. (NASDAQ:MEIP) stock from “an Overweight” to “an Equal weight”. The rating was released on March 25, 2022, according to finviz. We previously noted in another research note published on March 25, 2022 by Stifel that downgraded the stock from a Buy to a Hold with a price target of $2 for MEIP stock. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $1. The stock was initiated by Jefferies, who disclosed in a research note on February 03, 2022, to Buy and set the price objective to $4. In their research brief published September 22, 2020, Alliance Global Partners analysts initiated the MEI Pharma Inc. stock to Buy with a price target of $9.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
The latest trade, Performances and Moving Averages give us the following Picture
The share price of MEI Pharma Inc. (NASDAQ:MEIP) dipped -1.88% to close Thursday’s market session at $0.50, lower as compared to yesterday’s close. The stock price fluctuated between $0.4871 and $0.5423 throughout the trading session with the volume trading being 3665164 shares, which represented a significant variation when compared to the three months average volume of 6.03 million shares. The firm’s stock price fluctuated -11.86% within the last five trades and -20.00% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price decreased -83.20% in the last 6 months and -72.55% was subtracted to its value over the previous 3 months. MEIP stock is trading at a margin of -9.68%, -50.68% and -77.31% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, MEIP deals in the Healthcare domain. The stock is trading -85.89 percent below its 52-week high and 5.63 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -67.69. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does MEI Pharma Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
The stock’s market cap achieved a total value of $64.33 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 1.46 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 0.82, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 0.57 percent of MEI Pharma Inc. shares are owned by insiders, and 62.20 percent are held by financial institutions.